Regulus Therapeutics
RGLS
#7021
Rank
C$0.76 B
Marketcap
C$11.11
Share price
0.00%
Change (1 day)
396.57%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -C$66.2 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -C$62.9 Million a decrease over its 2023 earnings that were of -C$40.07 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -C$66.2 Million5.26%
2024 -C$62.9 Million56.97%
2023 -C$40.07 Million6.51%
2022 -C$37.62 Million2.53%
2021 -C$36.69 Million93.59%
2020 -C$18.96 Million-15.41%
2019 -C$22.41 Million-64.46%
2018 -C$63.04 Million-33.26%
2017 -C$94.45 Million-13.98%
2016 -C$0.11 Billion44.77%
2015 -C$75.85 Million-1.63%
2014 -C$77.11 Million203.6%
2013 -C$25.4 Million8.65%
2012 -C$23.38 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
C$12.38 B-19,287.12%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
C$2.59 B-4,114.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$10.93 B-17,036.90%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
C$17.81 B-27,699.15%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
C$12.69 B-19,756.54%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-C$0.15 Billion 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-C$0.17 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
C$0.17 B-374.76%๐Ÿ‡บ๐Ÿ‡ธ USA